• +1-646-491-9876
    • +91-20-67278686

    Search

    Ileal Sodium/Bile Acid Cotransporter Pipeline Review H1 2017

    Ileal Sodium/Bile Acid Cotransporter Pipeline Review H1 2017

    • Report Code ID: RW0001858684
    • Category Pharmaceuticals
    • No. of Pages 51
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H1 2017

    Summary

    Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. The latest report Ileal SodiumBile Acid Cotransporter - Pipeline Review, H1 2017, outlays comprehensive information on the Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Ileal Sodium/Bile Acid Co-transporter is encoded by SLC10A2 gene. It plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine and cholesterol metabolism. The molecules developed by companies in Pre-Registration, Phase II and Preclinical stages are 1, 4 and 4 respectively. Report covers products from therapy areas Gastrointestinal, Dermatology, Genetic Disorders, Metabolic Disorders and Infectious Disease which include indications Cholestasis, Non-Alcoholic Steatohepatitis (NASH) , Primary Biliary Cirrhosis, Alagille Syndrome, Primary Sclerosing Cholangitis, Progressive Familial Intrahepatic Cholestasis, Pruritus, Constipation, Hepatitis B, Non Alcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes.

    Furthermore, this report also reviews key players involved in Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2)
    - The report reviews Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Overview
    Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Companies Involved in Therapeutics Development
    Albireo Pharma Inc
    CJ HealthCare Corp
    GlaxoSmithKline Plc
    Scynexis Inc
    Shire Plc
    Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Drug Profiles
    A-4250 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CJ-14199 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug to Inhibit IBAT for Liver and Metabolic Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    elobixibat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2330672 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    maralixibat chloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SC-435 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit ASBT for Hepatitis B Virus Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    volixibat potassium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Dormant Products
    Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Product Development Milestones
    Featured News & Press Releases
    May 18, 2017: Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC
    May 16, 2017: Albireo Announces Two New U.S. Patents Allowed for A4250 with Term into 2031
    Apr 27, 2017: Albireo Announces Elobixibat Data from Japan to be Presented at DDW 2017
    Apr 22, 2017: Promising Pediatric Data for Albireo's A4250 to be Presented at The International Liver Congress 2017
    Apr 05, 2017: EASL Selects Albireo's A4250 Data for Late Breaker Presentation
    Feb 01, 2017: Albireo Announces Submission of New Drug Application for Elobixibat in Japan
    Nov 15, 2016: Albireo's Lead Product Candidate for Orphan Pediatric Liver Disease Accepted Into European Medicines Agency's PRIME Program
    Oct 03, 2016: Albireo Announces Positive Top-Line Phase 3 Results for Elobixibat in Japan
    Sep 30, 2016: EA Pharma and Mochida Pharmaceutical Announce the Results of Phase 3 Study of AJG533 for Chronic Constipation Conducted in Japan
    Jul 29, 2016: Shire SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for Adults Who Have Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis
    Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP625 for Rare Gastrointestinal Condition
    Nov 12, 2015: Albireo to Present A4250 Clinical Data at the 2015 AASLD Annual Meeting
    Nov 10, 2015: Albireo Announces the Initiation in Japan of a Phase 3 Clinical Trial of Elobixibat in Chronic Constipation by Ajinomoto Pharmaceuticals
    Apr 09, 2015: Shire Reports Topline Results from First of Three Placebo-Controlled Phase 2 Studies of SHP625 (LUM001) in Children with Alagille Syndrome
    Feb 05, 2015: Initiation of a Phase II Trial for A4250, the Company's Lead Compound for Cholestatic Liver Diseases and NASH
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Albireo Pharma Inc, H1 2017
    Pipeline by CJ HealthCare Corp, H1 2017
    Pipeline by GlaxoSmithKline Plc, H1 2017
    Pipeline by Scynexis Inc, H1 2017
    Pipeline by Shire Plc, H1 2017
    Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Albireo Pharma Inc
    CJ HealthCare Corp
    GlaxoSmithKline Plc
    Scynexis Inc
    Shire Plc

    Request for Sample

    Report Url https://www.reportsweb.com//ileal-sodium-bile-acid-cotransporter-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//ileal-sodium-bile-acid-cotransporter-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//ileal-sodium-bile-acid-cotransporter-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments